Group items tagged

The report is titled as 'Chronic Obstructive Pulmonary Disease (COPD) Treatment Market: Opportunity Analysis and Future Assessment 2022-2030'. An overview of conceptual frameworks, analytical approaches of the Chronic Obstructive Pulmonary Disease (COPD) Treatment market is the main objective of the report, which further consists the market opportunity and insights of the data involved in the making of the respective market.

The "Asthma Drugs Market: Opportunity Analysis and Future Assessment 2022-2030" research report offers a comprehensive and an in-depth evaluation of the progressive market trends, growth areas, opportunities, drivers, and restraints, which would allow clients and stakeholders to line up their market strategies as stated in present & future market dynamics. The Asthma Drugs Market is estimated to escalate at around 5.3% CAGR during 2022-30. A strategic assessment of the market growth trajectory in the forecast period, whilst taking into account the Covid-19 impact on the industry, is also included in the research study, with certain information established by research experts.  The global asthma drugs market is estimated to reach at a value of US$ 24.0 Bn by the end of 2022 and expected to reach at a value of US$ 36.3 Bn by 2030 with a significant CAGR of 5.3% Request a Sample Copy of this Report @: https://reportsandinsights.com/sample-request/4683 Asthma Drugs Introduction Asthma is basically an inveterate respiratory ailment obstructing the respiratory tracts of the lungs owing to the mucus production, inflammation, and contraction of muscles. Also, Chronic Obstructive Pulmonary Disease (COPD) is further a chronic ailment induced by blockage in the respiratory tracts leading to trouble in breathing, with the main reason being smoking tobacco. Asthma Drugs Market Dynamics One of the major factors that is accelerating the demand of asthma drugs across the global markets is the rapidly growing prevalence of asthma and COPD patients across the world. In addition to that, the rapid growth in the geriatric population across the globe along with numerous technological advancements in the healthcare sector is also playing a positive role in boosting the demand of asthma drugs across the market. Moreover, growth in pipeline products as well as rise in numerous initiatives commenced by the regulatory bodies and non-government associations in order to sp

PBR Staff Writer Published 01 May 2014 The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (GSK) Incruse Ellipta (umeclidinium) for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Umeclidinium is a once-daily long-acting muscarinic antagonist (LAMA), a type of bronchodilator also known as an anticholinergic.

Healthcare stocks dominated news on Monday as buy-outs and clinical trials made for some of the day's biggest movers.